Recent Company News

• 02:16 AM ET Aug 14, 2025
  

  Vivesto doses first patient in Paccal Vet dose-finding study in cats with solid tumors

• 05:05 AM ET Mar 18, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:14 AM ET Aug 12, 2025
  

  Vivesto reports Q2 EPS (SEK0.02) vs year-ago (SEK0.02) (SEK 0.24, 0.00)

• 02:20 AM ET May 08, 2025
  

  Vivesto reports Q1 EPS (SEK0.02) vs year-ago (SEK0.02) (SEK 0.24, 0.00)

• 02:08 AM ET Apr 01, 2025
  

  Vivesto announced positive preclinical efficacy data was obtained in an animal model of hematological cancer (SEK 0.25, 0.00)

• 02:18 AM ET Mar 31, 2025
  

  Vivesto signs agreement with Kazia Therapeutics to acquire full rights, including all intellectual property and trademarks rights for the drug candidate Cantrixil for $1M (SEK 0.24, 0.00)

• 02:19 AM ET Mar 18, 2025
  

  Vivesto licenses Apealea to China's Zhida Pharmaceutical; upfront and milestone payments worth up to $5.85M, as well as sales royalties when the product reaches the market (SEK 0.22, 0.00)